CY1124577T1 - Καινοτομες ενωσεις τετραζολιου και η χρηση τους στη θεραπεια της φυματιωσης - Google Patents

Καινοτομες ενωσεις τετραζολιου και η χρηση τους στη θεραπεια της φυματιωσης

Info

Publication number
CY1124577T1
CY1124577T1 CY20211100770T CY211100770T CY1124577T1 CY 1124577 T1 CY1124577 T1 CY 1124577T1 CY 20211100770 T CY20211100770 T CY 20211100770T CY 211100770 T CY211100770 T CY 211100770T CY 1124577 T1 CY1124577 T1 CY 1124577T1
Authority
CY
Cyprus
Prior art keywords
treatment
tuberculosis
tetrazole compounds
novel tetrazole
novel
Prior art date
Application number
CY20211100770T
Other languages
Greek (el)
English (en)
Inventor
Carlos Alemparte-Gallardo
Lourdes ENCINAS
Jorge ESQUIVIAS PROVENCIO
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of CY1124577T1 publication Critical patent/CY1124577T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20211100770T 2017-08-17 2021-08-31 Καινοτομες ενωσεις τετραζολιου και η χρηση τους στη θεραπεια της φυματιωσης CY1124577T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382574 2017-08-17
PCT/EP2018/072205 WO2019034729A1 (en) 2017-08-17 2018-08-16 NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS

Publications (1)

Publication Number Publication Date
CY1124577T1 true CY1124577T1 (el) 2022-07-22

Family

ID=59713960

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100770T CY1124577T1 (el) 2017-08-17 2021-08-31 Καινοτομες ενωσεις τετραζολιου και η χρηση τους στη θεραπεια της φυματιωσης

Country Status (19)

Country Link
US (1) US11072591B2 (enExample)
EP (1) EP3668856B1 (enExample)
JP (1) JP7410017B2 (enExample)
KR (1) KR102661367B1 (enExample)
CN (1) CN110997651B (enExample)
AU (1) AU2018317812C1 (enExample)
CA (1) CA3072854A1 (enExample)
CY (1) CY1124577T1 (enExample)
DK (1) DK3668856T3 (enExample)
ES (1) ES2885573T3 (enExample)
HR (1) HRP20211326T1 (enExample)
HU (1) HUE055732T2 (enExample)
LT (1) LT3668856T (enExample)
PL (1) PL3668856T3 (enExample)
PT (1) PT3668856T (enExample)
RS (1) RS62267B1 (enExample)
SI (1) SI3668856T1 (enExample)
SM (1) SMT202100515T1 (enExample)
WO (1) WO2019034729A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184718A (zh) * 2018-11-15 2020-05-22 鲁南制药集团股份有限公司 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途
CN115403533B (zh) * 2021-05-28 2023-08-25 永康市第一人民医院 一种1-苯乙烯基-1,2,3-三氮唑化合物及其制备方法和应用
CN116102483B (zh) * 2021-11-09 2025-01-17 中国医学科学院药物研究所 取代吡咯-2,5-二酮类化合物及其制备方法和用途
CN116726018A (zh) * 2023-08-02 2023-09-12 上海市肺科医院(上海市职业病防治院) 一种贝达喹啉、德拉马尼、氯法齐明和吡嗪酰胺的联用和应用
CN117379430B (zh) * 2023-10-11 2026-07-21 深圳市第三人民医院(深圳市肝病研究所) 一种地拉韦啶的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID24105A (id) 1997-07-22 2000-07-06 Shionogi & Co Komposisi untuk mengobati atau mencegah glomerulopati
JP2010523599A (ja) 2007-04-05 2010-07-15 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド クリックケミストリーを使用した炭酸脱水酵素−ixのための分子イメージングプローブの開発
WO2017066964A1 (en) 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Also Published As

Publication number Publication date
PT3668856T (pt) 2021-09-15
CA3072854A1 (en) 2019-02-21
PL3668856T3 (pl) 2021-12-13
SI3668856T1 (sl) 2021-11-30
US20200231555A1 (en) 2020-07-23
KR102661367B1 (ko) 2024-04-29
BR112020003247A2 (pt) 2020-08-18
CN110997651B (zh) 2023-01-03
CN110997651A (zh) 2020-04-10
RS62267B1 (sr) 2021-09-30
LT3668856T (lt) 2021-09-27
RU2020110818A3 (enExample) 2021-10-11
KR20200041915A (ko) 2020-04-22
AU2018317812C1 (en) 2021-08-26
EP3668856B1 (en) 2021-06-23
JP7410017B2 (ja) 2024-01-09
AU2018317812A1 (en) 2020-02-20
AU2018317812B2 (en) 2021-04-15
HUE055732T2 (hu) 2021-12-28
RU2020110818A (ru) 2021-09-17
ES2885573T3 (es) 2021-12-14
US11072591B2 (en) 2021-07-27
EP3668856A1 (en) 2020-06-24
HRP20211326T1 (hr) 2021-11-26
WO2019034729A1 (en) 2019-02-21
JP2020531425A (ja) 2020-11-05
DK3668856T3 (da) 2021-09-20
SMT202100515T1 (it) 2021-11-12

Similar Documents

Publication Publication Date Title
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
MX391812B (es) Agonista fxr derivado de esteroides.
CY1124387T1 (el) Μεθοδος για παραγωγη νεας χημικης ενωσης που περιεχει αζωτο ή αλατος αυτης, και παραγωγη ενδιαμεσου της ιδιας
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
EA201891644A1 (ru) Антибактериальные соединения и их применение
CR20180541A (es) Inhibidores de bromodominios
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
CY1124851T1 (el) Νεες ενωσεις
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
CY1122286T1 (el) Ετεροδικυκλικες ενωσεις και η χρηση τους για τη θεραπευτικη αντιμετωπιση της φυματιωσης
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
CY1125546T1 (el) Σανφετρινεμη η ενα αλας η εστερας αυτης για χρηση στη θεραπεια μυκοβακτηριακης λοιμωξης
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
JOP20190049A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
CY1124151T1 (el) Ενωσεις